The alteration in expression of B cell lymphoma-2
Introduction
Apoptosis was first formally described and named in 1972 as a stereotypic morphological response to many different types of cellular insult different from necrosis. Apoptosis is one of the major mechanisms of cell death in response to cancer therapies [1, 2] . Inhibiting apoptosis is widely accepted as a crucial step in the transition from normal to cancer cells. Alterations in susceptibility to apoptosis not only contribute to neoplastic development but also can enhance resistance to conventional anticancer therapies, such as radiation and cytotoxic agents [3] .
One of the suggested mechanisms of resistance to cytotoxic antineoplastic drugs is the alteration in expression of B cell lymphoma-2 (Bcl-2) family of protein members. The Bcl-2 family of proteins consists of 25 pro-and antiapoptotic members, which interact to maintain a balance between newly forming cells and old dying cells. The phosphorylation at Ser 70 of Bcl-2 by protein kinase C may activate or inactivate its antiapoptotic function, depending on cell type and deathsignaling molecules [4] [5] [6] [7] [8] [9] [10] [11] . Accumulating evidence points to a crucial role for the Bcl-2 family in regulating apoptosis in cancer cells, and it is clear that exploiting this relationship is an attractive approach for novel anticancer agents [12] . However, some attempts to target Bcl-2 clinically have not demonstrated major antitumor activity [13] .
Galectin-3 (Gal-3) is a member of animal lectins which are a family of carbohydrate-binding proteins characterized by their affinity for β-galactoside and a sequence of the carbohydrate recognition domain (CRD). Gal-3, a 31-kDa unique chimeric gene product, consists of three structural domains: an NH2-terminal domain, repeated collagen-like sequence, and COOH-terminal containing a single CRD [14, 15] . Gal-3 is widely expressed in cancer cells as well as in epithelial and immune cells [16] [17] [18] [19] [20] . The expression of Gal-3 is related with tumor invasion and metastatic potential of several types of cancer [17, [19] [20] [21] [22] . It has been shown that Gal-3 is a multifunctional oncogenic protein and regulates cell growth, cell adhesion, cell proliferation, angiogenesis, and apoptosis [14, [23] [24] [25] [26] [27] [28] [29] [30] . Of note, Gal-3, which contains the Asp-Trp-Gly-Arg (NWGR) anti-death motif of the Bcl-2 family, inhibits cell apoptosis induced by some chemotherapeutic agents in cancer cells [31] [32] [33] [34] [35] . In addition, nuclear export of Gal-3 phosphorylated at Ser 6 regulates its antiapoptotic activity in response to chemotherapeutic drugs [36] [37] [38] [39] . These apparent similarities between Bcl-2 and Gal-3 in their antiapoptotic functions and the posttranslational modification of serine phosphorylation lead us to surmise the possibility that targeting Gal-3 with antiBcl-2 treatment might be therapeutically valuable.
This review presents the current knowledge of roles of Bcl-2 family and Gal-3 in the regulation of apoptosis. Furthermore, we will discuss the clinical significances and future perspectives of Gal-3 as improvement of the efficacy of anticancer drug chemotherapy.
The classification of the Bcl-family of proteins
To date, 25 members of the Bcl-2 family of proteins have been identified [40] . These proteins are localized to mitochondria, smooth endoplasmic reticulum, and perinuclear membranes. They are divided into three subfamilies according to their proand antiapoptotic effects and the presence of Bcl-2 homology (BH) domains [41] . The proapoptotic Bcl-2 family members are subdivided into two classes: the multidomain effector proteins and the BH3-only proteins. The multidomain members include Bcl-2-associated x protein (Bax) and Bcl-2 homologous agonist killer (Bak). They contain structural features of BH 1-3 domains and are critically important because when they are activated, they change from monomers to oligomers that disrupt the integrity of the mitochondrial outer membrane-a process called mitochondrial outer membrane permeabilization (MOMP) [12, 42, 43] . MOMP causes the leakage of components such as cytochrome c from the intermembrane space of mitochondria into the cytoplasm. Other proapoptotic proteins, such as Bcl-2 interacting mediator of cell death (Bim), BH3 interacting domain death agonist (Bid), Bcl-2-associated death promoter (Bad), p53 upregulated modulator of apoptosis (Puma), and Noxa (also known as PMAIP1) contain only the BH3 domain. BH3-only proteins can bind to and regulate the antiapoptotic Bcl-2 proteins to promote apoptosis. BH3-only protein signaling is essential for the initiation of the mitochondrial apoptotic pathway. On the other hand, the antiapoptotic subfamily contains the Bcl-2, Bcl-2-related gene long isoform (Bcl-XL), B cell lymphomaw (Bcl-w), myeloid cell leukemia-1 (Mcl-1), and so on, which suppress apoptosis and possess three or four BH domains [44] . These antiapoptotic proteins all promote cell survival by inactivating their proapoptotic Bcl-2 family counterparts and preserving mitochondrial outer membrane integrity [41] .
3 The interaction among the Bcl-2 family of proteins Generally, two major pathways lead to caspase activation and apoptosis in cells: the extrinsic pathway and the intrinsic pathway. The extrinsic cell death pathway can function independently of mitochondria and is triggered by Fas ligand or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), subsequently activating caspase 8. Caspase 8 transforms Bid into truncated Bid (tBid), which activates the intrinsic apoptotic pathway and initiates a cascade of caspase activation [45] . By contrast, the intrinsic cell death pathway, also known as the mitochondrial apoptotic pathway, is activated by various signals including radiation, cytotoxic drugs, cellular stress, and growth factor withdrawal and involves the release of components such as cytochrome c from the mitochondrial membrane space.
Most cells express a variety of both anti-and proapoptotic Bcl-2 proteins, and the interaction between proteins within this family dictates whether a cell survives or dies [46] . Here, we provide an overview of the role of Bcl-2 family in apoptosis (Fig. 1) . However, the exact mechanisms of how Bcl-2 proteins interconnect to regulate MOMP and apoptosis after these signals have been controversially discussed [12, 43, 44] .
The "direct activation" model divides BH3-only proteins into two groups, which are activators (such as Bim, tBid, and maybe Puma) and sensitizers (such as Bad or Noxa). Activators directly bind to Bax/Bak and induce their oligomerization, resulting in Bax/Bak pore formation and MOMP. Antiapoptotic Bcl-2 proteins can sequester the BH3-only activators and prevent Bax/Bak oligomerization. On the other hand, sensitizers act as decoys and inhibit engaging of antiapoptotic Bcl-2 proteins with activators or Bax/Bak [47, 48] .
The second "derepression" model suggests that Bax/Bak is always active, and the antiapoptotic Bcl-2 proteins prevent cell death by binding to Bax/Bak. The role of the BH3-only proteins is to bind to the antiapoptotic Bcl-2 family proteins to release active Bax/Bak. The active Bax/Bak is then able to integrate into the mitochondrial outer membrane, create oligomerization, and form pores resulting in MOMP [49, 50] .
Recently, Leber et al. proposed the third "embedded together" model, which combines features of both models [12, 51] . In this model, antiapoptotic Bcl-2 proteins sequester both active Bax and BH3-only activators, and BH3-only sensitizers displace Bax and BH3-only activators from the antiapoptotic proteins.
These significant interactions occur at the mitochondrial outer membrane. However, further investigation is needed to fully elucidate the mechanisms of how Bcl-2 family proteins bind to each other. It has been shown that antiapoptotic Bcl-2 family members contain a hydrophobic binding pocket formed by the folding of their BH1, BH2, and BH3 domains, and BH3-only proteins can bind into this groove via their BH3 domain [12, 41, 46] . Bcl-2/Bax heterodimerization, which prevents Bax oligomerization, is also very important for antiapoptotic function. Interestingly, the NWGR motif in Bcl-2 has been shown to be critical for Bcl-2/Bax heterodimerization [52] .
Antiapoptotic Bcl-2 family members as targets for cancer treatment
Pathologic overexpression of the antiapoptotic Bcl-2 family proteins subverts the natural apoptotic response and contributes to tumor initiation and progression as well as to resistance to chemotherapy. Consequently, evidence about a crucial role for the Bcl-2 family in regulating apoptosis in cancer suggests that these family members are attractive targets for the treatment of cancers [53] . Although many agents have been developed, they have some problems individually.
The first agent targeting Bcl-2 that entered clinical trials was a Bcl-2 antisense, oblimersen sodium, an 18 mer antisense oligonucleotide designed to target the first six codons of Bcl-2 mRNA [54] . The combination treatment of oblimersen with an anticancer drug increased the chemotherapeutic effect in phase I studies [55] [56] [57] . In phase II and III clinical trials [44] , the addition of oblimersen improved clinical outcomes in combination with other anticancer chemotherapeutic agents in patients with melanoma and relapse or refractory CLL [58, 59] , while it failed to improve outcomes in patients with small cell lung cancer (SCLC) [60] .
Gossypol, a polyphenol derived from the cottonseed plant, was the first natural compound discovered that demonstrated inhibition of Bcl-2, Bcl-XL, and Mcl-1 [61] . In preclinical studies, many groups have shown gossypol's potent proapoptotic activity [62] [63] and is also known to cause male infertility [64] . The two Bcl-2 inhibitor drugs furthest in clinical development are GX15-070 (obatoclax) and ABT-737. Obatoclax was discovered as a result of a high-throughput screen of natural compounds that disrupted protein interactions in the Bcl-2 family and was the first pan antiapoptotic Bcl-2 protein inhibitor to be described [65] . This small molecule indole bipyrrole compound has been shown to bind to all antiapoptotic Bcl-2 family and disrupt protein-protein interactions in the family in vitro [66] . Obatoclax has been tested in phase I clinical trials in patients with hematological and myeloid malignancies and was well tolerated [67, 68] . However, in more recent phase II studies in patients with relapsed or refractory classical Hodgkin lymphoma and relapsed SCLC, obatoclax displayed limited clinical activity [69, 70] . Interestingly, Vogler et al. suggested that the mechanism of cell killing by obatoclax in vitro is not exclusively via the Bcl-2 family-regulated mitochondrial apoptosis pathway [64] , and limited clinical activity may be because of inadequate inhibition of Bcl-2 family proteins [13] . Obatoclax had also been reported to induce both neurological symptoms in early clinical trials of patients with CLL as well as neuronal toxicity in mice [67, 71] , which might be because of targets outside the Bcl-2 family.
Perhaps, the most advanced compounds are the ABT-737 and ABT-263 molecules. ABT-737 was developed as a rational Bcl-2 inhibitor using nuclear magnetic resonance structure-based design with the BH3 region of Bad [72] . ABT-737 binds to and inhibits Bcl-2, Bcl-XL, and Bcl-w with higher affinities than any of other Bcl-2 inhibitors. This drug exhibits a dependence on key components of the intrinsic apoptotic pathway, including Bax, Bak, and caspase 9 [64] and is extremely effective at enhancing the cytotoxicity of a variety of chemotherapy agents in acute lymphoblastic leukemia in vitro and in vitro [73] . However, ABT-737 has problems for drug delivery and does not bind to Mcl-1, with resistance observed in cells that express Mcl-1 [74, 75] . To overcome the delivery problems, ABT-263 (Navitoclax) was developed for use in the clinic. Navitoclax is an oral version of ABT-737 and shares a similar binding profile and affinities to Bcl-2, Bcl-XL, and Bcl-w proteins. It is active as a single agent in SCLC xenografts and enhanced the activity of chemotherapy agents in preclinical studies or phase I studies of B cell lymphoma, multiple myeloma, and SCLC [76] [77] [78] . Although many clinical trials are currently underway, Bcl-2 targeting by Navitoclax showed limited single-agent activity against advanced and recurrent SCLC in phase II study, which has recently been completed [79] . Some strategies are also being developed to complement the activity by neutralizing Mcl-1 [80] [81] [82] .
Efforts to target the Bcl-2 family for cancer therapy have yielded remarkable advances in the past decade. However, a single BH3 mimetic to Bcl-2 family may not be sufficient as monotherapeutic to cure cancer patients. Furthermore, accumulating clinical trial failures lead us to predict other factor related with the regulation of apoptosis or anticancer drug resistance by Bcl-2 family proteins.
Regulation of apoptosis by Gal-3 in cancer cells
The galectins are a family of mammalian β-galactoside binding proteins that share highly conserved CRDs. To date, 15 galectin members have been identified, and they are classified into three subgroups depending on their structural differences and the number of CRDs within their polypeptide chains [14, 83] . Gal-3 is the exclusive member of the chimera-type galectin subgroup and contains one CRD. Gal-3 is expressed broadly in many tumor cells, and clinical evidences have shown that the expression of Gal-3 is associated with the carcinogenesis and malignant potential in melanoma; lymphoma; and thyroid, gastric, colon, uterine, and renal cancers [16-22, 84, 85] .
The roles of Gal-3 in human cancer are well documented [86] . Gal-3 has been shown to be involved in cell growth, cell proliferation, cell differentiation, cell adhesion, angiogenesis, apoptosis, tumor progression and metastasis mainly through binding to glycoproteins. In particular, Gal-3 is shown to be involved in the regulation of apoptosis [30] . The process of the antiapoptotic action includes phosphorylation, translocation, and regulation of survival signaling and the caspase pathway (Fig. 2) [87] .
Phosphorylation of Gal-3 plays the role of an "on-off" switch for protein-carbohydrate interactions. The major site of phosphorylation is Ser 6 and a minor site is Ser
12
, as identified by mass spectrophotometric analysis [88, 89] . Overexpression of wild-type Gal-3 inhibits apoptosis induced by stimuli, while substitution of Ser 6 of Gal-3 by the nonphosphorylatable alanine inhibits its antiapoptotic function [34] . These results demonstrate that Gal-3 phosphorylation is critical for the regulation of its antiapoptotic signaling activity.
Recent evidence has shown that Gal-3 translocates either from the cytosol or the nucleus to the mitochondria following exposure to apoptotic stimuli such as anticancer drugs and block changes in the mitochondrial membrane potential, thereby preventing apoptosis [39, 90] . Phosphorylated wildtype Gal-3 exported from the nucleus to the cytoplasm and protected cancer cells from drug-induced apoptosis while nonphosphorylated Ser 6 mutant Gal-3 is neither exported from the nucleus nor protected cancer cells from drug-induced apoptosis [36] . Other groups have also reported that Gal-3 is found in the cytoplasm and perinuclear mitochondrial membranes, where it is involved in the control of apoptosis [38, 91] . The translocation of Gal-3 is carried out via at least two independent nuclear pathways: a passive diffusion and an active transport [92] . Synexin, a calcium-dependent and phospholipid-binding protein, contributes to the translocation of Gal-3 to mitochondria [39] . The translocation of Gal-3 is necessary for its effect on apoptosis regulation.
Several reports suggest that intracellular Gal-3 may directly affect the mitochondrial integrity, leading to the inhibition of both cytochrome c release from mitochondria and the downstream effector caspase-3 [39, 87] . Gal-3 can also attenuate the depolarization of the mitochondrial membrane through decrease of Bad expression [35] . In addition, Gal-3 has been shown to regulate the expression of several molecules in the survival signaling pathway. Firstly, phosphorylated Gal-3 increases the activity of the mitogen-activated protein kinase pathway, such as pERK, which is known to be involved in the regulation of mitochondrial stability and apoptosis, subsequently induces Bad phosphorylation [36] . Akt activated by Gal-3 also inhibits apoptosis by blocking transformation of Bid into tBid, which is essential for cytochrome c release from the mitochondrial intermembrane space [93] . Accumulating data strongly suggest that Gal-3 has a significant relevance to Bcl-2 family proteins in the regulation of apoptosis and is a candidate target protein to suppress antiapoptotic activity.
Clinical perspective of Gal-3
Many researchers, who consider Gal-3 as a therapeutic target for several cancers, have invented and developed the inhibitor for it [94] . The thiodigalactoside diester Td131_1 has been reported as a highly specific small molecule inhibitor of Gal-3 [95] . This small molecule has a high affinity and specificity for Gal-3 due to the specific interactions of its two ester moieties with Arg 144 and Arg 186 of Gal-3. Td131_1 was shown to promote apoptosis, chemosensitivity, and radiosensitivity in papillary thyroid cancer (PTC) cell lines and ex vivo PTC [96] . Moreover, as one of the candidates for the treatment of cancers by the application of a Gal-3 inhibitory approach, a novel therapy has been reported using modified citrus pectin (MCP). GCS-100, which is a MCP in the clinical development, binds to Gal-3 as an antagonist by targeting the CRD. Activity has been observed in animal melanoma and breast, colon, and prostate cancer models [97] [98] [99] Model for the regulation of apoptosis by Gal-3. Anticancer drugs can induce DNA damage, which causes Gal-3 phosphorylated by Casein Kinase 1 (CK1) translocate from the nuclear to cytoplasm. Gal-3 upregulates the ERK pathway and induces Bad phosphorylation, leading to mitochondrial stabilization. Akt activated by Gal-3 inhibits apoptosis by blocking transformation of Bid into tBid, which is essential for cytochrome c release from the mitochondrial intermembrane space. After treatment of proapoptotic agents, Gal-3 in cytoplasm decreases Bad expression and attenuates the depolarization of the mitochondrial membrane. Consequently, the stabilization of the mitochondrial membrane prevents cytochrome c release and subsequent caspase activation, resulting in suppression of apoptosis and resistance to chemotherapeutic agents cancer and CLL [100] . Studies of the safety of GCS-100 in patients with CLL and multiple myeloma are ongoing (GCS-100, http://clinicaltrials.gov). It has also been reported to show anti-myeloma activity with synergy in combination with dexamethasone, bortezomib, or PI11195 without affecting normal lymphocyte viability in preclinical studies [101] . As mentioned above, Mcl-1 has been recognized as an important determinant of chemoresistance. Interestingly, GCS-100 is shown to induce dose-and time-dependent decreases in Mcl-1 and Bcl-XL levels via caspase-dependent pathway accompanied by a rapid induction of Noxa protein [100] . Thus, GCS-100 not only suppresses Gal-3 multiple role in the regulation of apoptosis but also complements the effect of Bcl-2 targeting therapy by neutralizing Mcl-1. Furthermore, we suggest another mechanism of how targeting the CRD of Gal-3 relates with Bcl-2 family in the regulation of apoptosis. Although Gal-3 is not a member of the Bcl-2 family, it is possible that Gal-3 can sequester Bax like antiapoptotic Bcl-2 family proteins and regulate apoptosis because Gal-3 shares significant structural properties with Bcl-2. Both proteins are rich in proline, glycine, and alanine amino acid residues in their N-terminal and contain the NWGR motif in the Cterminal domain. This NWGR motif designated as the antideath motif is found in the BH-1 domain of Bcl-2 [102] . Intriguingly, the NWGR motif in Bcl-2 is significant for Bcl-2/Bax heterodimerization, which prevents Bax oligomerization [52] . It was also reported that an amino acid substitution of Gly to Ala in the NWGR motif of Gal-3 abrogated its apoptosis-resistance properties [31, 91] . Thus, it is not unreasonable to expect that Gal-3 can replace or mimic Bcl-2 by binding to Bax using this motif and regulate antiapoptosis. Since sugar-binding antagonists of Gal-3 such as GCS-100 targets the CRD domain, they may occupy the NWGR motif in the CRD, subsequently resulting in release of Bax from Gal-3 and Bax oligomerization. Gal-3 might be a mitochondrial associated apoptotic regulator through interaction with Bcl-2 family proteins.
The best results for patients with cancer may be achieved by appropriate drug combinations [43] . Finally, we propose a novel combination therapy model in Fig. 3 based on the following: (a) Gal-3 has multiple role in the regulation of apoptosis; (b) GCS-100, an antagonist of Gal-3, decreases Mcl-1 expression, which has been recognized as a determinant of chemoresistance; and (c) it is possible that Gal-3 might replace or mimic antiapoptotic Bcl-2 and regulate antiapoptosis by binding to Bax using the NWGR motif. On the other hand, Gal-3 that highly expresses in diverse cancers have multiple roles in the regulation of apoptosis (as shown in Fig. 2 ). Gal-3 may replace or mimic Bcl-2 by binding to Bax through the NWGR motif, which is critical for the antiapoptotic function of both Bcl-2 and Gal-3 proteins. c We propose a novel combination therapy model. Combination therapy targeting Gal-3 using sugar-binding antagonist with the conventional anti-Bcl-2 treatment leads to suppression of antiapoptotic function of Gal-3 itself. Interestingly, GCS-100, which binds to Gal-3 as an antagonist, is shown to reduce Mcl-1 expression and regulate the other bcl-2 family proteins. In addition, targeting the CRD of Gal-3 containing the NWGR motif may induce release of Bax from Gal-3, subsequently resulting in MOMP example, ABT-263 binds to and inhibits Bcl-2, Bcl-XL, and Bcl-w, resulting in effective enhancement of the cytotoxicity of several chemotherapy agents. However, in the instance where cancer cells highly express Mcl-1, ABT-263 may not result in substantial antitumor activity clinically. The suppression of Mcl-1 via the caspase-dependent pathway by Gal-3 inhibitor is useful for cancers that highly express Mcl-1 and show resistance to ABT-263. Moreover, the inhibition of Gal-3 roles in other apoptotic and survival signaling pathways against cancers that express elevated levels of Gal-3 will help Bcl-2 targeting therapy efficiency. In addition, targeting the CRD of Gal-3 may induce the release of Bax from Gal-3, subsequently resulting in MOMP.
Conclusions
Gal-3 can provide the theoretical foundation for a new therapeutic target for improving chemotherapy of cancers. Although much remains to be explored, the apparent similarity between Bcl-2 and Gal-3 in their antiapoptotic functions leads us to surmise that targeting Gal-3 with anti-Bcl-2 treatment is therapeutically valuable. Combination therapy targeting Gal-3 may lead to the improvement of efficacy in anti-Bcl-2 treatment in cancers and may result in one of the best approaches targeting Bcl-2 family proteins. Based on the limited success of anti-Bcl-2 drugs to improve clinical outcome of cancer patients, we propose that prior to initiation of clinical trials, the level of Gal-3 in the cancer cells should be determined. If the cells are positive for Gal-3, the anti-Bcl-2 treatment should include a Gal-3 antagonist to ensure that it is silenced as well.
